Endogenous metabolite bilirubin suppresses esophageal squamous cell carcinoma by activating PERK-dependent translational repression
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2027
DOI: 10.1016/j.bbadis.2026.168441 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2027. Verfasst von Minlei Dong und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Zhejiang University, Hangzhou, 310058, China. Hauptthemen laut MEDLINE: eIF-2 Kinase, Bilirubin, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Zhejiang Province Natural Science Foundation, Medical and Health Research Project of Zhejiang Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Bilirubin, an endogenous heme catabolite with potent antioxidant properties, has been inversely associated with cancer risk across multiple malignancies; however, its clinical relevance and the underlying molecular mechanisms in esophageal squamous cell carcinoma (ESCC) remain incompletely understood. Here, we retrospectively analyzed a cohort of 2011 patients with ESCC and found that higher serum bilirubin levels were associated with improved overall survival and served as an independent favorable prognostic factor. Mechanistically, physiological bilirubin directly engaged protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) and activated the PERK-eIF2α signaling axis, resulting in translational repression and suppression of ESCC proliferation. This translational repression was associated with altered cell cycle progression in vitro. In xenograft models, bilirubin treatment inhibited tumor growth and was accompanied by increased eIF2α phosphorylation and reduced proliferative activity. Together, these findings demonstrate that higher physiological bilirubin is associated with favorable prognosis in ESCC and bilirubin suppresses tumor progression via PERK-mediated translational repression, providing mechanistic insights into the role of the PERK-eIF2α axis in bilirubin-mediated tumor suppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Zhejiang University, Hangzhou, 310058, China.
- Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Han…
- School of Pharmacy, Zhejiang University, Hangzhou, 310058, China; Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou Fir…
- Zhejiang Cancer Hospital, Hangzhou, 310022, China.
- Zhejiang Cancer Hospital, Hangzhou, 310022, China. Electronic address: chenzj@zjcc.org.cn.
- School of Pharmacy, Zhejiang University, Hangzhou, 310058, China. Electronic address: hdjiang@zju.edu.cn.
Förderung
- Zhejiang Province Natural Science Foundation
- Medical and Health Research Project of Zhejiang Province
- National Natural Science Foundation of China
Zitieren
APA
Dong, M., Li, P., Luo, J., Zhang, Y., Pan, X., Zhou, H., Lin, N., Gao, Y., Li, N., Zhu, J., Chen, Z., & Jiang, H. (2027). Endogenous metabolite bilirubin suppresses esophageal squamous cell carcinoma by activating PERK-dependent translational repression. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. https://doi.org/10.1016/j.bbadis.2026.168441
Vancouver
Dong M, Li P, Luo J, Zhang Y, Pan X, Zhou H, et al. Endogenous metabolite bilirubin suppresses esophageal squamous cell carcinoma by activating PERK-dependent translational repression. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2027. doi:10.1016/j.bbadis.2026.168441
BibTeX
@article{Dong2027,
author = {Dong, Minlei and Li, Ping and Luo, Jun and Zhang, Yingqiong and Pan, Xiaoyi and Zhou, Hui and Lin, Nengming and Gao, Yun and Li, Ningning and Zhu, Jing and Chen, Zhongjian and Jiang, Huidi},
title = {Endogenous metabolite bilirubin suppresses esophageal squamous cell carcinoma by activating PERK-dependent translational repression},
journal = {Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease},
year = {2027},
doi = {10.1016/j.bbadis.2026.168441}
}
EUVIMED